Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK

P. R. Breeze, C. Thomas, H. Squires, A. Brennan, C. Greaves, P. Diggle, E. Brunner, A. Tabák, L. Preston, J. Chilcott

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: To analyse the cost-effectiveness of different interventions for Type 2 diabetes prevention within a common framework. Methods: A micro-simulation model was developed to evaluate the cost-effectiveness of a range of diabetes prevention interventions including: (1) soft drinks taxation; (2) retail policy in socially deprived areas; (3) workplace intervention; (4) community-based intervention; and (5) screening and intensive lifestyle intervention in individuals with high diabetes risk. Within the model, individuals follow metabolic trajectories (for BMI, cholesterol, systolic blood pressure and glycaemia); individuals may develop diabetes, and some may exhibit complications of diabetes and related disorders, including cardiovascular disease, and eventually die. Lifetime healthcare costs, employment costs and quality-adjusted life-years are collected for each person. Results: All interventions generate more life-years and lifetime quality-adjusted life-years and reduce healthcare spending compared with doing nothing. Screening and intensive lifestyle intervention generates greatest lifetime net benefit (£37) but is costly to implement. In comparison, soft drinks taxation or retail policy generate lower net benefit (£11 and £11) but are cost-saving in a shorter time period, preferentially benefit individuals from deprived backgrounds and reduce employer costs. Conclusion: The model enables a wide range of diabetes prevention interventions to be evaluated according to cost-effectiveness, employment and equity impacts over the short and long term, allowing decision-makers to prioritize policies that maximize the expected benefits, as well as fulfilling other policy targets, such as addressing social inequalities.

Original languageEnglish
Pages (from-to)1136-1144
Number of pages9
JournalDiabetic Medicine
Volume34
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Workplace
Cost-Benefit Analysis
Carbonated Beverages
Quality-Adjusted Life Years
Taxes
Costs and Cost Analysis
Population
Life Style
Blood Pressure
Diabetes Complications
Health Care Costs
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Cholesterol
Delivery of Health Care

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Breeze, P. R., Thomas, C., Squires, H., Brennan, A., Greaves, C., Diggle, P., ... Chilcott, J. (2017). Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK. Diabetic Medicine, 34(8), 1136-1144. https://doi.org/10.1111/dme.13349

Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK. / Breeze, P. R.; Thomas, C.; Squires, H.; Brennan, A.; Greaves, C.; Diggle, P.; Brunner, E.; Tabák, A.; Preston, L.; Chilcott, J.

In: Diabetic Medicine, Vol. 34, No. 8, 01.08.2017, p. 1136-1144.

Research output: Contribution to journalArticle

Breeze, PR, Thomas, C, Squires, H, Brennan, A, Greaves, C, Diggle, P, Brunner, E, Tabák, A, Preston, L & Chilcott, J 2017, 'Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK', Diabetic Medicine, vol. 34, no. 8, pp. 1136-1144. https://doi.org/10.1111/dme.13349
Breeze, P. R. ; Thomas, C. ; Squires, H. ; Brennan, A. ; Greaves, C. ; Diggle, P. ; Brunner, E. ; Tabák, A. ; Preston, L. ; Chilcott, J. / Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK. In: Diabetic Medicine. 2017 ; Vol. 34, No. 8. pp. 1136-1144.
@article{37e32a7b95734b15adc10043ec6c0819,
title = "Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK",
abstract = "Aim: To analyse the cost-effectiveness of different interventions for Type 2 diabetes prevention within a common framework. Methods: A micro-simulation model was developed to evaluate the cost-effectiveness of a range of diabetes prevention interventions including: (1) soft drinks taxation; (2) retail policy in socially deprived areas; (3) workplace intervention; (4) community-based intervention; and (5) screening and intensive lifestyle intervention in individuals with high diabetes risk. Within the model, individuals follow metabolic trajectories (for BMI, cholesterol, systolic blood pressure and glycaemia); individuals may develop diabetes, and some may exhibit complications of diabetes and related disorders, including cardiovascular disease, and eventually die. Lifetime healthcare costs, employment costs and quality-adjusted life-years are collected for each person. Results: All interventions generate more life-years and lifetime quality-adjusted life-years and reduce healthcare spending compared with doing nothing. Screening and intensive lifestyle intervention generates greatest lifetime net benefit (£37) but is costly to implement. In comparison, soft drinks taxation or retail policy generate lower net benefit (£11 and £11) but are cost-saving in a shorter time period, preferentially benefit individuals from deprived backgrounds and reduce employer costs. Conclusion: The model enables a wide range of diabetes prevention interventions to be evaluated according to cost-effectiveness, employment and equity impacts over the short and long term, allowing decision-makers to prioritize policies that maximize the expected benefits, as well as fulfilling other policy targets, such as addressing social inequalities.",
author = "Breeze, {P. R.} and C. Thomas and H. Squires and A. Brennan and C. Greaves and P. Diggle and E. Brunner and A. Tab{\'a}k and L. Preston and J. Chilcott",
year = "2017",
month = "8",
day = "1",
doi = "10.1111/dme.13349",
language = "English",
volume = "34",
pages = "1136--1144",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK

AU - Breeze, P. R.

AU - Thomas, C.

AU - Squires, H.

AU - Brennan, A.

AU - Greaves, C.

AU - Diggle, P.

AU - Brunner, E.

AU - Tabák, A.

AU - Preston, L.

AU - Chilcott, J.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Aim: To analyse the cost-effectiveness of different interventions for Type 2 diabetes prevention within a common framework. Methods: A micro-simulation model was developed to evaluate the cost-effectiveness of a range of diabetes prevention interventions including: (1) soft drinks taxation; (2) retail policy in socially deprived areas; (3) workplace intervention; (4) community-based intervention; and (5) screening and intensive lifestyle intervention in individuals with high diabetes risk. Within the model, individuals follow metabolic trajectories (for BMI, cholesterol, systolic blood pressure and glycaemia); individuals may develop diabetes, and some may exhibit complications of diabetes and related disorders, including cardiovascular disease, and eventually die. Lifetime healthcare costs, employment costs and quality-adjusted life-years are collected for each person. Results: All interventions generate more life-years and lifetime quality-adjusted life-years and reduce healthcare spending compared with doing nothing. Screening and intensive lifestyle intervention generates greatest lifetime net benefit (£37) but is costly to implement. In comparison, soft drinks taxation or retail policy generate lower net benefit (£11 and £11) but are cost-saving in a shorter time period, preferentially benefit individuals from deprived backgrounds and reduce employer costs. Conclusion: The model enables a wide range of diabetes prevention interventions to be evaluated according to cost-effectiveness, employment and equity impacts over the short and long term, allowing decision-makers to prioritize policies that maximize the expected benefits, as well as fulfilling other policy targets, such as addressing social inequalities.

AB - Aim: To analyse the cost-effectiveness of different interventions for Type 2 diabetes prevention within a common framework. Methods: A micro-simulation model was developed to evaluate the cost-effectiveness of a range of diabetes prevention interventions including: (1) soft drinks taxation; (2) retail policy in socially deprived areas; (3) workplace intervention; (4) community-based intervention; and (5) screening and intensive lifestyle intervention in individuals with high diabetes risk. Within the model, individuals follow metabolic trajectories (for BMI, cholesterol, systolic blood pressure and glycaemia); individuals may develop diabetes, and some may exhibit complications of diabetes and related disorders, including cardiovascular disease, and eventually die. Lifetime healthcare costs, employment costs and quality-adjusted life-years are collected for each person. Results: All interventions generate more life-years and lifetime quality-adjusted life-years and reduce healthcare spending compared with doing nothing. Screening and intensive lifestyle intervention generates greatest lifetime net benefit (£37) but is costly to implement. In comparison, soft drinks taxation or retail policy generate lower net benefit (£11 and £11) but are cost-saving in a shorter time period, preferentially benefit individuals from deprived backgrounds and reduce employer costs. Conclusion: The model enables a wide range of diabetes prevention interventions to be evaluated according to cost-effectiveness, employment and equity impacts over the short and long term, allowing decision-makers to prioritize policies that maximize the expected benefits, as well as fulfilling other policy targets, such as addressing social inequalities.

UR - http://www.scopus.com/inward/record.url?scp=85018568486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018568486&partnerID=8YFLogxK

U2 - 10.1111/dme.13349

DO - 10.1111/dme.13349

M3 - Article

C2 - 28294392

AN - SCOPUS:85018568486

VL - 34

SP - 1136

EP - 1144

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 8

ER -